001437499 000__ 04959cam\a2200529\a\4500
001437499 001__ 1437499
001437499 003__ OCoLC
001437499 005__ 20230309004151.0
001437499 006__ m\\\\\o\\d\\\\\\\\
001437499 007__ cr\un\nnnunnun
001437499 008__ 210622s2021\\\\sz\\\\\\o\\\\\000\0\eng\d
001437499 019__ $$a1257666604
001437499 020__ $$a9783030623517$$q(electronic bk.)
001437499 020__ $$a3030623513$$q(electronic bk.)
001437499 020__ $$z3030623505
001437499 020__ $$z9783030623500
001437499 0247_ $$a10.1007/978-3-030-62351-7$$2doi
001437499 035__ $$aSP(OCoLC)1257292465
001437499 040__ $$aYDX$$beng$$epn$$cYDX$$dGW5XE$$dEBLCP$$dOCLCO$$dOCLCF$$dUKAHL$$dOCLCQ$$dCOM$$dOCLCO$$dOCLCQ
001437499 049__ $$aISEA
001437499 050_4 $$aRM315
001437499 08204 $$a615.7/8$$223
001437499 24500 $$aModern CNS drug discovery :$$breinventing the treatment of psychiatric and neurological disorders /$$cRudy Schreiber, editor.
001437499 260__ $$aCham :$$bSpringer,$$c2021.
001437499 300__ $$a1 online resource
001437499 336__ $$atext$$btxt$$2rdacontent
001437499 337__ $$acomputer$$bc$$2rdamedia
001437499 338__ $$aonline resource$$bcr$$2rdacarrier
001437499 5050_ $$aPART I -- Introduction -- Innovator, Entrepreneur, Leader: The Tripartite Drug Discovery Neuroscientist -- PART II -- Innovation in the Discovery of Novel Therapeutic Approaches -- Drug Discovery in CNS: Finding a Target for What? -- Neurogenomics with Application to Schizophrenia and Other Major Neuropsychiatric Diseases with Complex Heredity -- Epigenetics in Drug Discovery: Achievements and Challenges -- Conventional Behavioral Models and Readouts in Drug Discovery: The Importance of Improving Translation -- Safety and Drug Metabolism: Toward NCE and First in Human -- The Various Forms of Non-invasive Brain Stimulation and Their Clinical Relevance -- Is Non-invasive Brain Stimulation the Low-Hanging Fruit? -- PART III -- Translational Medicine and Technology -- Electrophysiology: From Molecule to Cognition, from Animal to Human -- MRI in CNS Drug Development -- Positron Emission Tomography in Drug Development -- Application of Cognitive Test Outcomes for Clinical Drug Development -- Exciting Research in the Field of Sexual Psychopharmacology: Treating Patients with Inside Information -- A Paradigm Shift from DSM-5 to Research Domain Criteria: Application to Translational CNS Drug Development -- PART IV -- Clinical Development and Regulatory Approval -- The Special Challenges of Developing CNS Drugs -- Phase 1 Clinical Trials in Psychopharmacology -- Early Development of Erenumab for Migraine Prophylaxis -- Microdosing Psychedelics as a Promising New Pharmacotherapeutic -- Partnering with the FDA.
001437499 506__ $$aAccess limited to authorized users.
001437499 520__ $$aThis textbook provides a comprehensive overview of the currently used concepts, approaches and technologies in the discovery and development of new treatments for the full spectrum of disorders of the central nervous system. It guides the reader through all essential steps, from finding an innovative idea, to the registration of a new drug. Divided into four sections, the book starts by presenting a broad perspective on current approaches in central nervous system (CNS) drug discovery. The second section addresses the generation of ideas for the identification of targets and novel treatment strategies; covers core functions in early discovery, and provides an example of a novel treatment paradigm: brain stimulation. The third section highlights strategies and technologies in translational CNS drug discovery. In an effort to bridge the gap between discovery and clinical development, it also covers brain imaging, EEG and cognitive testing approaches. The fourth section extensively discusses the clinical phase of drug development, covering the basics of early clinical testing for psychopharmacological drugs. The book's final chapter addresses the registration for newly developed drugs. Written by experts from academia and industry, the book covers important basics and best practices, as well as recent developments in drug discovery. Offering in-depth insights into the world of drug development, it represents essential reading for early researchers who want to prepare for a career in drug discovery in academia or industry.
001437499 588__ $$aOnline resource; title from PDF title page (SpringerLink, viewed June 30, 2021).
001437499 650_0 $$aPsychopharmacology.
001437499 650_0 $$aCentral nervous system$$xChemotherapy.
001437499 650_0 $$aDrug development.
001437499 650_6 $$aPsychopharmacologie.
001437499 650_6 $$aSystème nerveux central$$xChimiothérapie.
001437499 650_6 $$aMédicaments$$xDéveloppement.
001437499 655_0 $$aElectronic books.
001437499 7001_ $$aSchreiber, Rudy,$$eeditor.
001437499 77608 $$iPrint version:$$tModern CNS drug discovery.$$dCham : Springer, 2021$$z3030623505$$z9783030623500$$w(OCoLC)1197851980
001437499 852__ $$bebk
001437499 85640 $$3Springer Nature$$uhttps://univsouthin.idm.oclc.org/login?url=https://link.springer.com/10.1007/978-3-030-62351-7$$zOnline Access$$91397441.1
001437499 909CO $$ooai:library.usi.edu:1437499$$pGLOBAL_SET
001437499 980__ $$aBIB
001437499 980__ $$aEBOOK
001437499 982__ $$aEbook
001437499 983__ $$aOnline
001437499 994__ $$a92$$bISE